AMG 319

Drug Profile

AMG 319

Alternative Names: AMG319

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Developer Amgen; Cancer Research UK
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Head and neck cancer
  • No development reported Haematological malignancies

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Haematological-malignancies(Second-line therapy or greater) in USA (PO, Capsule)
  • 01 Dec 2016 Amgen completes a phase-I trial for Haematological malignancies (Second-line therapy or greater) in USA (NCT01300026)
  • 16 Oct 2015 Phase-I development for Haematological malignancies (Second-line therapy or greater) is ongoing in USA (NCT01300026)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top